April 2026
LSD
What April 2026's 8 new studies found, synthesized from the papers below. All LSD research →
The synthesis
Synthesized from 7 studies in the library · AI-generated, grounded in the abstracts below
Found by searching the library for LSD, lysergic acid diethylamide, lysergide, then ranked by relevance.
Research on LSD in April 2026 primarily consisted of reviews and commentaries, with no new clinical trials reported. The evidence suggests LSD has therapeutic potential for conditions like depression and fibromyalgia, but findings are based on historical data, animal models, and proposed mechanisms rather than recent human trials. A key caveat is the lack of empirical support for mechanisms like repressed memory recovery and the methodological challenges in psychedelic research.
Confidence in the evidence
Insufficient- No new clinical trials or empirical human studies on LSD were reported in the provided abstracts.
- The evidence consists of reviews, commentaries, and one animal study, which provide limited direct evidence for human effects.
- The reviews highlight significant methodological hurdles, such as placebo control and lack of standardized protocols.
- The animal study shows sex- and route-dependent effects, but its translation to humans is unclear.
How we rate confidence
Confidence reflects the strength of the underlying evidence, not whether the result is favorable. It weighs the number and size of studies, their design (randomized trials count for more than observational or single-case work), how consistently they point the same way, and their risk of bias.
Tiers run from Insufficient to High. High is rare in this field: small, early, or open-label studies land lower even when their direction is encouraging.
Evidence by study
Direction is each study's finding relative to your question: Supports, Opposes, No effect, Mixed, or Unclear.
| Study | Design | Sample size | Direction | Finding |
|---|---|---|---|---|
| Evaluating the evidence for repressed memory recovery in psychedelic contexts 2026 | scoping review | 53 | Unclear | The review found limited empirical support for mechanisms by which LSD might recover repressed memories. |
| Psychedelics: Historical Context, Emerging Science, and Future Clinical Frontiers 2026 | commentary | Supports | The commentary notes LSD's therapeutic promise in mental health treatment but emphasizes the need for rigorous validation. | |
| A New Use for an Old Compound: Microdosing LSD to Reduce Fibromyalgia Symptoms 2026 | animal study | Supports | Microdosed LSD improved pain-related behaviors in a sex- and route-dependent manner in a mouse model of fibromyalgia. | |
| Dorsal Raphe Revisited: A Systems Neuroscience Lens on Psychedelic Drug Action 2026 | review | Unclear | The review traces historical research on LSD's effects on the dorsal raphe, noting early hypotheses were later revised. | |
| [LSD revisited: Mechanisms of action and therapeutic potential in mental health]. 2026 | review | Supports | The review discusses LSD's potential for treatment-resistant depression via 5-HT2A receptor modulation and neuroplasticity, but notes methodological hurdles. | |
| Psycholytic Therapy Using LSD: a Realist Review. 2026 | realist review | Supports | The review found that psycholytic therapy with LSD showed potential to improve severe mental health conditions when specific therapeutic practices were followed. | |
| Psychedelic Therapies for Comorbid Major Depressive Disorder and Chronic Pain: A Review of Putative Mechanisms of Action. 2026 | narrative review | Supports | The review supports LSD as a unified therapeutic approach for comorbid MDD and chronic pain through multiple proposed mechanisms. |
The review found limited empirical support for mechanisms by which LSD might recover repressed memories.
scoping review Sample size: 53
The commentary notes LSD's therapeutic promise in mental health treatment but emphasizes the need for rigorous validation.
commentary
Microdosed LSD improved pain-related behaviors in a sex- and route-dependent manner in a mouse model of fibromyalgia.
animal study
The review traces historical research on LSD's effects on the dorsal raphe, noting early hypotheses were later revised.
review
The review discusses LSD's potential for treatment-resistant depression via 5-HT2A receptor modulation and neuroplasticity, but notes methodological hurdles.
review
The review found that psycholytic therapy with LSD showed potential to improve severe mental health conditions when specific therapeutic practices were followed.
realist review
The review supports LSD as a unified therapeutic approach for comorbid MDD and chronic pain through multiple proposed mechanisms.
narrative review
Points of agreement
- Multiple reviews agree that LSD has therapeutic potential for mental health conditions like depression and chronic pain.
- The proposed mechanisms often involve 5-HT2A receptor modulation and neuroplasticity.
- All reviews note the need for more rigorous, ethically guided research.
Conflicts
- The scoping review on repressed memory found limited empirical support for mechanisms, while other reviews are more optimistic about therapeutic mechanisms.
- The animal study shows sex- and route-dependent effects, which may not generalize to human populations.
Gaps
- No new human clinical trials on LSD were reported in the provided studies.
- The durability of LSD's effects and long-term safety are not addressed.
- Methodological challenges like placebo control and blinding remain unresolved.
- Research on comorbid conditions (e.g., MDD and chronic pain) is largely unexplored.